The list of conditions that GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may help protect against keeps growing, according to research presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting.
Originally developed for type 2 diabetes and later approved for obesity, these drugs have already been shown in earlier studies to reduce the risk of heart attacks, strokes, kidney-disease progression and sleep apnoea. New data presented at ASCO 2026 added breast cancer to that list, suggesting a potential protective association worth further study.
How the drugs work
GLP-1 receptor agonists mimic a gut hormone that regulates appetite and blood sugar. By acting on centres that control hunger and on metabolic pathways, they produce substantial, sustained weight loss and improve a range of cardiometabolic markers. Their effects on inflammation and metabolism are thought to underlie the widening circle of apparent benefits.
What this means — and what it does not
Researchers caution that the breast-cancer finding, like many GLP-1 observations, is from observational and conference-stage data rather than a completed randomised trial. It points to a promising direction but is not yet a licence for these drugs to be used specifically to prevent cancer. Definitive answers will require prospective studies designed to test the question directly.
For now, the established role of GLP-1 medicines remains the treatment of type 2 diabetes and obesity, where they have transformed care for many patients. Clinicians emphasise that anyone considering these therapies should discuss benefits, side effects and individual risk factors with their doctor — and that they are not a substitute for screening, healthy diet and exercise.
As research continues, GLP-1 drugs have become one of the most closely watched areas in medicine, with trials underway across cardiology, nephrology and oncology to pin down exactly how far their benefits reach.